Current PTCA practice and clinical outcomes in the Netherlands: The real world in the pre-drug-eluting stent era

European Heart Journal

Volumn 25, Issue 13, 2004, Pages 1163-1170

  Agema, Willem R P ^a,b   Monraats, Pascalle S ^a,b   Zwinderman, Aeilko H ^c   De Winter, Robbert J ^c   Tio, René A ^d   Doevendans, Pieter A F M ^e   Waltenberger, Johannes ^f   De Maat, Moniek P M ^g   Frants, Rune R ^a   Atsma, Douwe E ^a   Van Der Laarse, Arnoud ^a   Van Der Wall, Ernst E ^a   Jukema, J Wouter ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g TNO   (Netherlands)

Author keywords

Percutaneous transluminal coronary angioplasty; Restenosis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HUMAN; HYPERTENSION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK FACTOR; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; NETHERLANDS; PROFESSIONAL PRACTICE; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; TREATMENT OUTCOME;

EID: 3042628062     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.05.006     Document Type: Article

References (19)

1. Fattori R., Piva T. Drug-eluting stents in vascular intervention. Lancet. 361(9353):2003;247-249
2. Pache J., Kastrati A., Mehilli J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J. Am. Coll. Cardiol. 41(8):2003;1283-1288
3. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23):2002;1773-1780
4. Agema W.R.P., Jukema J.W., Pimstone S.N., et al. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur. Heart J. 22(22):2001;2058-2074
5. Rensing B.J., Hermans W.R., Vos J., et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation. 88(3):1993;975-985
6. Weintraub W.S., Kosinski A.S., Brown III C.L., et al. Can restenosis after coronary angioplasty be predicted from clinical variables? J. Am. Coll. Cardiol. 21(1):1993;6-14
7. Kastrati A., Schomig A., Elezi S., et al. Predictive factors of restenosis after coronary stent placement. J. Am. Coll. Cardiol. 30(6):1997;1428-1436
8. Cutlip D.E., Chauhan M.S., Baim D.S., et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J. Am. Coll. Cardiol. 40(12):2002;2082-2089
9. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 82(4):1990;1193-1202
10. Klein J.P., Moeschberger M.L. Survival analysis. 1997;Springer, New York
11. Schemper M., Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics. 56(1):2000;249-255
12. Mehilli J., Kastrati A., Bollwein H., et al. Gender and restenosis after coronary artery stenting. Eur. Heart J. 24(16):2003;1523-1530
13. Tardif J.C., Gregoire J., Schwartz L., et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation. 107(4):2003;552-558
14. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348(16):2003;1537-1545
15. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14):2003;1315-1323
16. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331(8):1994;496-501
17. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N. Engl. J. Med. 331(8):1994;489-495
18. Mercado N., Boersma E., Wijns W., et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J. Am. Coll. Cardiol. 38(3):2001;645-652
19. Mak K.H., Faxon D.P. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur. Heart J. 24(12):2003;1087-1103